NEOpredict-OMD

Immunotherapy-based, multimodal treatment strategies in oligometastatic non-small cell lung cancer: A randomized, low-interventional clinical trial of local ablative therapy guided by metabolic treatment response

II

interventionell

National

PET/CT-guided, multimodal treatment strategy for OMD NSCLC as compared to a strategy that involves LAT of all known lesions

Status: In Vorbereitung

Zeitraum

2027

2030

Zentren

11

Keine Zentren gesucht

Patienten

155

07.10.2026

Klinische Settings

IVA, IVB

1st line

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Universitätsklinikum Essen

Förderer

NCT

Identifier

AIO-TRK-0426/ass

NEOpredict-OMD

2026-528364-25-00

Kontakt

Leitung

Prof. Dr. med. Marcel Wiesweg
Dr. med. Franziska Glanemann

Ansprechpartner*in

Prof. Dr. med. Marcel Wiesweg
E-Mail marcel.wiesweg@uk-essen.de